Skip Navigation LinksHome > May 2010 - Volume 25 - Issue 2 > Angiogenesis in Non-small Cell Lung Cancer: Imaging With Per...
Journal of Thoracic Imaging:
doi: 10.1097/RTI.0b013e3181d29ccf

Angiogenesis in Non-small Cell Lung Cancer: Imaging With Perfusion Computed Tomography

Ng, Quan Sing MBBS, MRCP*; Goh, Vicky MA, MBBChir, MRCP, FRCR, MD

Collapse Box


Manipulation of tumor vasculature has emerged as a promising therapeutic strategy in advanced non-small cell lung cancer (NSCLC). Bevacizumab has been licensed for first-line therapy in combination with standard chemotherapy in advanced NSCLC, whereas inhibitors of platelet-derived growth factor receptors and other tyrosine kinases are currently in clinical trials for the treatment of advanced NSCLC. Perfusion computed tomography is a promising biomarker in NSCLC. As a measure of tumor perfusion and angiogenesis, perfusion computed tomography may provide invaluable pharmacodynamic information in early-phase clinical trials, monitor the vascular effects of antiangiogenic or vascular-targeting drug treatment, and provide prognostic and predictive information. Current volumetric techniques, affording a coverage of up to 28 cm, permit clinically relevant, high-quality, whole tumor evaluation.

© 2010 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.